What is Orchid doing?


Orchid has a proactive education programme delivering awareness sessions, businesses and the community and around 120 awareness events or talks are currently provided by the Orchid team each year. Orchid provides several publications for anyone who has been affected by prostate cancer  including a Z-card which highlights the risk factors, signs and symptoms of prostate cancer.


Orchid produces an informative information leaflet on PSA testing, a male cancer booklet and is currently developing a stand alone prostate cancer booklet.


Orchid provides a National Male Cancer Telephone Helpline for anyone worried or affected by male cancer. This is a free service and is staffed by Orchid Male Cancer Information Nurse Specialists.

Orchid is delighted to have been awarded 3 years funding from the Big Lottery to deliver new support services for black African and Caribbean men at risk of or affected by prostate cancer. Click here to find out more about this project which Orchid is developing in association with Cancer Black Care. Please watch this space for further updates about the project’s progress.


Orchid funds a molecular biology and cancer genetics programme with a focus on identifying new genes associated with prostate and testicular tumour development and progression. It also funds the Orchid Tissue Bank, a collection of male cancer histopathology (cancerous tissue). The Tissue Bank has one of the largest collections of penile, prostate and testicular cancer tissue in Europe. The histopathology team collaborates with other genito-urinary research groups in the UK and the world including the Trans-Atlantic Prostate Group and conducts its own research into penile, prostate and testicular cancer. The Orchid tissue bank also supports studies which examine the potential causes and factors that are important in the development of cancer including lifestyle causes, so that we can try to prevent the disease occurring in the first place.

Melphalan (MEL-CAP)

Men who have more advanced prostate cancer are likely to have hormone therapy. This treatment usually works well at causing a remission in the disease and symptoms for a number of years. At some stage however, prostate cancer often stops responding to this type of treatment. Doctors call this hormone resistance.  This study is looking to see how well high dose melphalan chemotherapy can treat prostate cancer that is not responding to hormone therapy.  It is known that melphalan can kill prostate cancer cells however it causes a severe drop in blood cells, doctors have not been able to give as big a dose as they would like.


For more information on this research please click here

Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST)

A trial of triamcinolone with hormone therapy for prostate cancer (TRICREST). This study is looking at a steroid drug called triamcinolone for prostate cancer that has stopped responding to hormone therapy. The men taking part have triamcinolone alongside hormone therapy.The aim of the trial is to see if triamcinolone helps men who have prostate cancer that is no longer responding to hormone therapy.

For more information on this research please click here



Last reviewed 04/01/2018. Next review 04/07/2018.

Was this page useful?

  • Please type the code above, so you can submit the form.
  • This field is for validation purposes and should be left unchanged.